Results · Apr-Jun 2026
Novelix Pharmaceuticals Q1 FY27 results
Sales grew 65% to ₹36.9 crore from ₹22.4 crore in Apr-Jun 2025.
Operating profit grew 620% to ₹1.3 crore, an operating margin of 3.5% (up 2.7 points from a year ago).
Net profit grew 1002% to ₹1.2 crore from ₹0.11 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +47%, net profit +29%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 36.9 | 22.4 | +65% |
| Operating profit (EBITDA) | 1.3 | 0.2 | +620% |
| Operating margin | 3.5% | 0.8% | +2.7 pts |
| Net profit | 1.2 | 0.1 | +1002% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.